Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Non Operating Income (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Non Operating Income for 4 consecutive years, with -$2.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income fell 11183.35% to -$2.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.3 million, a 5109.18% decrease, with the full-year FY2024 number at -$74736.0, down 230.63% from a year prior.
  • Non Operating Income was -$2.8 million for Q3 2025 at bioAffinity Technologies, down from -$1.5 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $42764.0 in Q2 2023 to a low of -$2.8 million in Q3 2025.
  • A 4-year average of -$455035.0 and a median of -$22380.5 in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: surged 103.23% in 2023, then tumbled 11183.35% in 2025.
  • bioAffinity Technologies' Non Operating Income stood at -$1.1 million in 2022, then surged by 97.52% to -$28466.0 in 2023, then rose by 28.53% to -$20344.0 in 2024, then crashed by 13442.35% to -$2.8 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Non Operating Income are -$2.8 million (Q3 2025), -$1.5 million (Q2 2025), and -$24583.0 (Q1 2025).